Do utilization management controls for phototherapy increase the prescription of biologics?

Journal of Dermatological Treatment

Volumn 17, Issue 6, 2006, Pages 359-361

  Simpson, Gregory L ^a   Yelverton, Christopher B ^a   Rittenberg, Sheila ^b   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b National Psoriasis Foundation   (United States)

Author keywords

Biological therapy; Cost control; Psoriasis therapy

Indexed keywords

PHOTOSENSITIZING AGENT;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HOME CARE; HUMAN; LONG TERM CARE; PHOTOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; REIMBURSEMENT; REVIEW; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ULTRAVIOLET RADIATION;

BIOLOGICAL PRODUCTS; COST-BENEFIT ANALYSIS; HUMANS; PHOTOTHERAPY; PRACTICE GUIDELINES; PSORIASIS; UTILIZATION REVIEW;

EID: 34250164228     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630601028786     Document Type: Review

References (18)

1. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136-9.
2. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-7.
3. National Psoriasis Foundation. National Psoriasis Foundation: Statistics. National Psoriasis Foundation 2005 [cited 17 August]. URL: http://www. psoriasis.org/about/stats/
4. Feldman SR, Koo JY, Menter A, Bagel J. Decision points for the initiation of systemic treatment for psoriasis. J Am Acad Dermatol. 2005;53:101-7.
5. Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J. Strategy to manage the treatment of severe psoriasis: Considerations of efficacy, safety and cost. Expert Opin Pharmacother. 2003;4:1525-33.
6. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer. 1994;73:2759-64.
7. Griffiths CE, Clark CM, Chalmers RJ, Li Wan PA, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess. 2000;4:1-125.
8. Coven TR, Burack LH, Gilleaudeau P, Keogh M, Ozawa M, Krueger JG. Narrowband UV-B produces superior clinical and histopathological resolution of moderate to severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997;133:1514-22.
9. Karrer S, Eholzer C, Ackermann G, Landthaler M, Szeimies RM. Phototherapy of psoriasis: Comparative experience of different phototherapeutic approaches. Dermatology. 2001;202:108-15.
10. Housman TS, Rohrback JM, Fleischer AB Jr, Feldman SR. Phototherapy utilization for psoriasis is declining in the United States. J Am Acad Dermatol. 2002;46:557-9.
11. Guttman C. NPF/AAD working to increase phototherapy reimbursement. Dermatology Times. 2000;21:17.
12. Dalzell MD. HMOs' delicate balancing act: The art of setting copayments. Manag Care. 1997;6(12):48-50, 53-4.
13. Cameron H, Yule S, Moseley H, Dawe RS, Ferguson J. Taking treatment to the patient: Development of a home TL-01 ultraviolet B phototherapy service. Br J Dermatol. 2002;147:957-65.
14. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: An assessment of the benefits and risks. Br J Dermatol. 2005;152:597-615.
15. Jenner N, Campbell J, Plunkett A, Marks R. Cost of psoriasis: A study on the morbidity and financial effects of having psoriasis in Australia. Australas J Dermatol. 2002;43:255-61.
16. Yelverton CB, Kulkarni AS, Balkrishnan R, Feldman SR. Home ultraviolet B phototherapy: A cost-effective option for severe psoriasis. Manag Care Interface. 2006;19:33-6, 39.
17. Kulkarni AS, Balkrishnan R, Richmond DW, Pearce DJ, Feldman SR. Medication related factors affecting health care outcomes and costs in patients with psoriasis in the United States. J Am Acad Dermatol. 2005;52:27-31.
18. Nijsten T, Rolstad T, Feldman SR, Stern RS. Members of the National Psoriasis Foundation: More extensive disease and better informed about treatment options. Arch Dermatol. 2005;141:19-26.